MDPI and ACS Style
Moreno, I.; Hernández, T.; Calvo, E.; Fudio, S.; Kahatt, C.; Fernández, C.; Iglesias, J.L.; Corral, G.; Pérez-Ramos, L.; Montilla, L.;
et al. Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study. Pharmaceuticals 2024, 17, 182.
https://doi.org/10.3390/ph17020182
AMA Style
Moreno I, Hernández T, Calvo E, Fudio S, Kahatt C, Fernández C, Iglesias JL, Corral G, Pérez-Ramos L, Montilla L,
et al. Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study. Pharmaceuticals. 2024; 17(2):182.
https://doi.org/10.3390/ph17020182
Chicago/Turabian Style
Moreno, Irene, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Cristian Fernández, Jorge Luis Iglesias, Gema Corral, Laura Pérez-Ramos, Lola Montilla,
and et al. 2024. "Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study" Pharmaceuticals 17, no. 2: 182.
https://doi.org/10.3390/ph17020182
